Holen Sie sich die Stockscreener-App
24.88
5.74%
1.35
Schlusskurs vom Vortag:
$23.53
Offen:
$23.95
24-Stunden-Volumen:
1.15M
Relative Volume:
0.29
Marktkapitalisierung:
$4.20B
Einnahmen:
$56.99M
Nettoeinkommen (Verlust:
$-107.23M
KGV:
-30.35
EPS:
-0.8199
Netto-Cashflow:
$-142.55M
1W Leistung:
+11.97%
1M Leistung:
+14.39%
6M Leistung:
-5.72%
1J Leistung:
+171.91%
1-Tages-Spanne:
$23.20
$25.04
1-Wochen-Bereich:
$21.52
$23.86
52-Wochen-Spanne:
$6.69
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
24.88 | 4.20B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
509.53 | 129.15B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
241.37 | 96.36B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
797.20 | 82.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
881.00 | 55.40B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
381.90 | 43.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-16 | Eingeleitet | William Blair | Outperform |
| 2026-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2026-06-26 | Hochstufung | Jefferies | Hold → Buy |
| 2026-06-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-05-15 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2026-05-14 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 - GlobeNewswire Inc.
Why Tango Therapeutics Shares Are Falling Today - Quiver Quantitative
JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data - Investing.com
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com South Africa
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com UK
Form 4 Tango Therapeutics Inc For: 5 October By Investing.com - Investing.com Canada
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com Canada
Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares - Stock Titan
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Tango Therapeutics principal accounting officer sells $198k in stock - Investing.com
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com Canada
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
H.C. Wainwright raises Tango Therapeutics price target to $68 - investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Oct 01 '26 |
Sale |
24.47 |
27,000 |
660,796 |
115,743 |
| Jessica Newcomb | Officer |
Sep 22 '26 |
Proposed Sale |
22.33 |
15,231 |
340,108 |
0 |
| Newcomb Jessica | Principal Accounting Officer |
Sep 22 '26 |
Sale |
24.22 |
8,200 |
198,613 |
59,121 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Sale |
22.37 |
27,000 |
603,909 |
115,743 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Sale |
27.24 |
27,000 |
735,517 |
115,743 |
| ADAM CRYSTAL | Officer |
Aug 03 '26 |
Proposed Sale |
27.18 |
81,000 |
2,201,580 |
0 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Sale |
29.59 |
27,000 |
798,908 |
115,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
2.15%
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):